East Windsor, NJ— A recent study published inComplementary Therapies in Medicine Panahi, shows the role a combination of Sabinsa’s Curcumin C3 Complex/BioPerine plays in the context of diabetes. In the study, the combination works in a protective capacity in regards to maintenance of HDL functionality and in the reduction of non-HDL-C . The study also indicated a first in curcumin research, an shown improvement in Lp(a) [Lipoprotien(a)], which is a structural component of LDL.

“The overall conclusions in this study together with earlier studies on C3 Complex/BioPerine combination add to the body of science on its positive role in the health maintenance of diabetic subjects,” said Sabinsa founder Dr. Muhammed Majeed, who contributed to the published study, in a press release.

The study involved a total of 100 subjects with type-2 diabetes in a 12-week randomized double-blind placebo-controlled trial which showed favorable outcomes when using a combination of Sabinsa’s Curcumin C3 Complex (1,000 mg/day) and BioPerine (10 mg/day). Fifty members were in an active group and fifty members were in a placebo group. In the active group, the combination of C3 Complex/BioPerine was shown to reduce the atherogenic lipid indices including non-HDL cholesterol and Lp(a) and also indicated an increase in both HDL levels and functionality.

This the first time that a nutritional intervention has been shown in a clinical trial for curcuminoids to reduce Lp(a), which is a part of LDL cholesterol. Until now, PCSK9 inhibitors were the only drug intervention to reduce Lp(a) at a high expensive as an injectable.